ALSO NOTED: Orexigen gets positive Phase II results; AnorMED completes Mozobil enrollment; and much more...

> AnorMED has completed enrollment in a phase III trial of Mozobil for cancer patients. Release

> Orexigen Therapeutics has revealed positive Phase II results for Excalia, for the treatment of obesity. Excalia is a combination of two centrally-acting medications.  Release

> SkinMedica has received FDA approval for Desonate, for treatment for mild to moderate atopic dermatitis. Release

> Bristol-Myers Squibb Company announced that the FDA approved a new 300 mg single capsule formulation of Reyataz for the HIV-1 infection in adults as a part of combination therapy. Report

And Finally... Young people who get a new meningitis shot Menactra could be at higher risk for contracting Guillain-Barre syndrome. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.